the staff of the Ridgewood blog
Ridgewood NJ, on April 2, a team of researchers led by the US CDC COVID-19 Response Team published interim estimates of a prospective cohort study describing the effectiveness of the two-dose Pfizer-BioNTech and Moderna SARS-CoV-2 mRNA vaccines among healthcare and other frontline workers. The report, published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), describes data collected from December 14, 2020 to March 13, 2021, through the HEROES-RECOVER network of 8 US sites. Overall, 3,950 frontline workers (i.e., those who routinely are within 3 feet of other individuals as part of their occupation) with no prior laboratory documentation of SARS-CoV-2 infection were included in the analysis. Participants were actively monitored for COVID-19 symptoms and self-collected weekly nasal swabs which were tested for SARS-CoV-2 infection.
